Biotherapies in large vessel vasculitis

详细信息    查看全文

• 作者：G. Pazzola ; F. Muratore ; N. Pipitone ; C. Salvarani ; ^{salvarani.carlo@asmn.re.it" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Large vessel vasculitis ; Giant cell arteritis ; Takayasu arteritis ; Biological therapies ; Biotherapies
• 刊名：La Revue de Médecine Interne
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：37
• 期：4
• 页码：274-278
• 全文大小：596 K

文摘

The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.